---
title: "The Hang Seng Index opened flat, and the Hang Seng Tech Index rose by 0.38%"
description: "36Kr learned that the Hang Seng Index opened flat, and the Hang Seng Tech Index rose by 0.38%; INSILICO surged 45% on its first day of trading in Hong Kong; the semiconductor and defense military indu"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/271047440.md"
published_at: "2025-12-30T01:26:38.000Z"
---

# The Hang Seng Index opened flat, and the Hang Seng Tech Index rose by 0.38%

> 36Kr learned that the Hang Seng Index opened flat, and the Hang Seng Tech Index rose by 0.38%; INSILICO surged 45% on its first day of trading in Hong Kong; the semiconductor and defense military industry sectors led the gains, with SMIC rising over 2% and AVICHINA rising over 1%; the non-ferrous metals and electrical equipment sectors saw the largest declines, with Ganfeng Lithium falling over 5% and JunDa Co., Ltd. falling over 2%

36Kr learned that the Hang Seng Index opened flat, and the Hang Seng Tech Index rose by 0.38%; INSILICO surged 45% on its first day of trading in Hong Kong; the semiconductor and defense sectors led the gains, with SMIC rising over 2% and AVICHINA rising over 1%; the non-ferrous metals and electrical equipment sectors saw the largest declines, with Ganfeng Lithium falling over 5% and JunDa Co., Ltd. falling over 2%

### Related Stocks

- [02357.HK - AVICHINA](https://longbridge.com/en/quote/02357.HK.md)
- [03696.HK - INSILICO](https://longbridge.com/en/quote/03696.HK.md)
- [00981.HK - SMIC](https://longbridge.com/en/quote/00981.HK.md)
- [688981.CN - SMIC](https://longbridge.com/en/quote/688981.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 英矽智能發佈了由 AI 設計的 ISM5059，作為臨牀前 NLRP3 抑制劑的候選藥物 | 英矽智能開曼頂級公司已提名 ISM5059 作為預臨牀候選藥物，這是一種針對 NLRP3 的人工智能設計的小分子抑制劑。ISM5059 是通過 Pharma.AI 平台開發的，旨在通過抑制 NLRP3 的構象變化來治療炎症和代謝疾病。這一提 | [Link](https://longbridge.com/en/news/274977240.md) |
| 英矽智能在 ISM5411 研究中為首位患者進行劑量給藥 | 英矽智能在 ISM5411 研究中為首位患者給藥 | [Link](https://longbridge.com/en/news/272203151.md) |
| 英矽智能提名 ISM5059 作為新的 NLRP3 抑制劑用於炎症治療 | 英矽智能開曼頂級公司已提名 ISM5059 作為臨牀前候選藥物。ISM5059 是一種由人工智能驅動的外周作用 NLRP3 抑制劑，旨在治療各種炎症和代謝疾病。該分子是專門為 NLRP3 抑制而設計，採用了英矽智能的 Pharma.AI 平 | [Link](https://longbridge.com/en/news/274977231.md) |
| 英矽智能 IPO 後熱度不減 再籤 8.88 億美元大單 | 英矽智能在港股上市後簽署了與法國施維雅的 8.88 億美元研發合作協議，專注於抗腫瘤藥物的開發。儘管尚未盈利，英矽智能的核心產品 Rentosertib 被視為全球進展最快的 AI 藥物之一。此次合作採用風險共擔、收益共享的模式，英矽智能將 | [Link](https://longbridge.com/en/news/272620356.md) |
| 英矽智能結束 IPO 穩定化操作，完全行使超額配售選擇權 | 英矽智能開曼頂級公司已結束其香港 IPO 的穩定期，摩根士丹利亞洲有限公司完全行使了 1,420,3500 股的超額配售選擇權，約佔總髮行規模的 15%，每股價格為 24.05 港元。該公司確認符合香港的公眾持股要求，並表示沒有進行市場上的 | [Link](https://longbridge.com/en/news/273383010.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.